Non-randomized preprint on dapagliflozin and epicardial adipose tissue in HFpEF
Dapagliflozin linked to fat loss in heart failure patients
This preprint reports a non-randomized clinical trial in 60 patients with left ventricular diastolic dysfunction. The main finding is that a…
Adding dapagliflozin to standard care reduced epicardial fat in a small group of heart failure patients, though this preprint study needs co…
Rule-based Clinical Decision Support System Matches Expert Assessments in Heart Failure With Preserved Ejection Fraction
AI Helps Doctors Spot Heart Failure Faster
This prospective cohort study evaluated 134 patients with exertional dyspnea and preserved left ventricular ejection fraction. A rule-based …
A new AI tool helps doctors diagnose stiff heart failure faster by automating complex measurements during exercise tests with high accuracy.
Combined NT-proBNP, DLK-1, PSP-D, and PCSK-9 detection shows moderate diagnostic performance for HFpEF.
New blood markers may help diagnose heart failure with preserved ejection fraction more accurately
This prospective biomarker cohort study evaluated 58 HFpEF patients and 30 healthy controls to assess the diagnostic utility of specific bio…
Mixing four blood markers improves heart failure diagnosis accuracy compared to standard tests alone, offering a clearer path to early detec…
Spironolactone reduces cardiovascular events in HFpEF patients with increased LV mass or left atrial volume.
Spironolactone Saves Lives in Specific Heart Failure Types
This post hoc analysis of the TOPCAT randomized controlled trial evaluated spironolactone in 757 participants with heart failure with preser…
Spironolactone cuts death risk for heart failure patients with enlarged heart chambers, proving that heart size matters just as much as pump…
HFpEF probability scores rule out disease but show limitations in AF and obesity phenotypes.
HFpEF probability scores work well for typical cases but struggle with atrial fibrillation and obesity
This systematic review evaluated the performance of HFpEF probability scores (HFA-PEFF and H2FPEF) in patients with heart failure with prese…
Heart failure scores work well for typical cases but lose accuracy in patients with atrial fibrillation or obesity due to altered biological…
Network meta-analysis of pharmacotherapies shows GLP-1 RAs and SGLT2is reduce composite cardiovascular death and hospitalization in HFpEF.
New drugs may lower heart failure risk and improve walking distance for patients with preserved ejection fraction
This network meta-analysis evaluated 48,235 patients with heart failure with preserved ejection fraction (HFpEF) treated with various pharma…
New heart drugs lower death risk and hospital visits for patients with preserved ejection fraction while improving walking distance.
Lipidomics analysis identifies three molecular phenogroups in HFpEF, including high-risk group
Could a simple blood test reveal which heart failure patients face the highest risk?
An observational cohort study of 177 HFpEF patients and non-HF subjects in Belgian and Canadian cohorts used plasma lipidomics to identify t…
Blood fat patterns group heart failure patients into distinct types, revealing one high-risk group with severe scarring and lower survival c…
Higher prognostic nutritional index associated with lower MACE and mortality in AF and HFpEF patients
Study links better nutritional scores to lower heart risks in patients with two heart conditions
A retrospective cohort study of 734 patients with atrial fibrillation and HFpEF found that higher prognostic nutritional index (PNI) was ind…
Patients with better nutrition scores face a 63% lower risk of heart events and an 83% lower risk of death compared to those with poorer sco…